Key Points
- CFO Oluyemi Okupe sold 12,313 Hims & Hers shares for approximately $354,861, reducing his direct stake by 4.66% to 251,804 shares. The transaction was made under a pre-arranged Rule 10b5-1 trading plan.
- Hims & Hers reported quarterly revenue of $753.21 million, up 38.2% year over year and above estimates, but its adjusted loss of $0.37 per share was substantially worse than the expected $0.05 loss.
- The stock opened at $28.00, while analysts maintained a consensus “Hold” rating with an average price target of $32.43; institutional investors and hedge funds own 63.52% of the company.
Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 12,313 shares of the business's stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $28.82, for a total value of $354,860.66. Following the transaction, the chief financial officer directly owned 251,804 shares in the company, valued at $7,256,991.28. This trade represents a 4.66% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Oluyemi Okupe also recently made the following trade(s):
- On Wednesday, August 19th, Oluyemi Okupe sold 4,938 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.99, for a total value of $148,090.62.
- On Monday, August 17th, Oluyemi Okupe sold 9,388 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.89, for a total value of $261,831.32.
- On Monday, July 6th, Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock. The stock was sold at an average price of $36.49, for a total value of $261,377.87.
- On Monday, June 22nd, Oluyemi Okupe sold 18,197 shares of Hims & Hers Health stock. The shares were sold at an average price of $34.03, for a total transaction of $619,243.91.
Hims & Hers Health Trading Up 0.4%
Shares of HIMS opened at $28.00 on Friday. The company has a current ratio of 0.93, a quick ratio of 0.87 and a debt-to-equity ratio of 4.21. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $65.30. The firm has a 50-day moving average price of $30.06 and a 200 day moving average price of $27.60. The firm has a market capitalization of $6.53 billion, a P/E ratio of -44.45 and a beta of 2.42.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.32). The firm had revenue of $753.21 million for the quarter, compared to analysts' expectations of $698.90 million. Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.Hims & Hers Health's revenue for the quarter was up 38.2% on a year-over-year basis. During the same period last year, the firm earned $0.17 earnings per share. Sell-side analysts forecast that Hims & Hers Health, Inc. will post -0.16 EPS for the current year.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in HIMS. Bienville Capital Management LLC purchased a new position in shares of Hims & Hers Health during the second quarter worth $27,242,000. Engineers Gate Manager LP acquired a new stake in shares of Hims & Hers Health in the second quarter valued at $232,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Hims & Hers Health in the 2nd quarter valued at $147,000. Baird Financial Group Inc. raised its holdings in shares of Hims & Hers Health by 384.6% in the 2nd quarter. Baird Financial Group Inc. now owns 65,575 shares of the company's stock valued at $2,273,000 after buying an additional 52,043 shares during the period. Finally, Nykredit A S acquired a new position in Hims & Hers Health during the 2nd quarter worth about $222,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.
Key Stories Impacting Hims & Hers Health
Here are the key news stories impacting Hims & Hers Health this week:
- Neutral Sentiment: CFO Oluyemi Okupe sold 12,313 shares worth approximately $355,000, reducing his position by 4.66%. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, making it a weaker standalone bearish signal. CFO SEC filing
- Neutral Sentiment: COO Michael Chi sold 14,027 shares for about $398,000, while insider Soleil Boughton sold 6,236 shares for approximately $174,000. Both sales were made through pre-arranged Rule 10b5-1 plans; however, the cluster of insider sales may still reinforce investor caution. Insider SEC filing
- Negative Sentiment: Multiple law firms announced or promoted a securities class action against HIMS involving investors who purchased shares between August 4, 2025, and July 29, 2026. The deadline to seek lead-plaintiff status is November 2, 2026, increasing headline and litigation risk. Securities class action report
- Negative Sentiment: The lawsuits stem from allegations related to the FTC’s complaint, including potential misstatements or omissions concerning Hims & Hers’ privacy, data-sharing, billing and business practices. The allegations remain unproven, but could lead to legal costs, regulatory consequences and reputational damage. HIMS lawsuit allegations
Wall Street Analysts Forecast Growth
Several research firms have issued reports on HIMS. Bank of America raised their target price on Hims & Hers Health from $30.00 to $32.00 and gave the stock a "neutral" rating in a research note on Tuesday, August 11th. Wall Street Zen raised Hims & Hers Health from a "sell" rating to a "hold" rating in a research note on Saturday, August 15th. Deutsche Bank Aktiengesellschaft increased their price target on Hims & Hers Health from $25.00 to $26.00 and gave the stock a "hold" rating in a report on Tuesday, August 11th. Barclays reduced their price objective on shares of Hims & Hers Health from $39.00 to $35.00 and set an "overweight" rating on the stock in a report on Friday, August 21st. Finally, Canaccord Genuity Group upped their target price on shares of Hims & Hers Health from $32.00 to $40.00 and gave the company a "buy" rating in a research report on Wednesday, July 1st. Three investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $32.43.
Read Our Latest Report on Hims & Hers Health
Hims & Hers Health Company Profile
(
Get Free Report)
Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides access to personalized care through digital platforms, including the Hims and Hers brands. The company connects consumers with licensed healthcare professionals for online consultations, treatment plans and prescription medications, where appropriate.
Its services address areas such as sexual health, hair loss, skin care, mental health, weight management and primary care. Hims & Hers also offers over-the-counter products, supplements and personal-care items, with products and prescriptions delivered directly to customers through its fulfillment network and pharmacy partners.
The company was established in 2016 and initially focused on men's health before expanding under the Hers brand to serve women and broaden its health-care offerings.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
